Market revenue in 2023 | USD 580.1 million |
Market revenue in 2030 | USD 1,054.3 million |
Growth rate | 8.9% (CAGR from 2023 to 2030) |
Largest segment | Electrochemical biosensor |
Fastest growing segment | Electrochemical Biosensor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Electrochemical Biosensor, Optical Biosensor, Other |
Key market players worldwide | Abbott Laboratories, DexCom Inc, PHC Holdings Corp, Roche Holding AG, Sanofi SA, Bayer AG, Wendy Novak Diabetes Institute, GlySens, Trividia Health, Ascensia Diabetes Care, Roche Holding AG ADR, LifeScan, PalmSens, Biolinq, SB Pharma Solutions, Nutrix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glucose biosensors market will help companies and investors design strategic landscapes.
Electrochemical biosensor was the largest segment with a revenue share of 57.75% in 2023. Horizon Databook has segmented the Japan glucose biosensors market based on electrochemical biosensor, optical biosensor, other covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan glucose biosensors market , including forecasts for subscribers. This country databook contains high-level insights into Japan glucose biosensors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account